

Improving the health of the people in our communities by  
providing quality, compassionate care to everyone, every time

**March 14, 2022**

**Change Notification Information**  
**New HPV testing & Test Codes**  
**Same Collection as Current method**

Sparrow Laboratories, your molecular laboratory service provider, is proud to announce the availability of the real-time PCR, FDA-approved **cobas**® HPV Test from Roche Diagnostics for Primary Screening in women 25 and older.

The **cobas**® HPV Test is performed on the fully automated **cobas**® 6800 System, for delivery of trustworthy results with a rapid turnaround time. This test individually identifies genotypes 16 and 18, the two highest-risk HPV genotypes responsible for more than 70 percent of cervical cancer cases, while simultaneously detecting 12 other high risk HPV genotypes (HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). One test, in one run, from one patient sample delivers 3 results, eliminating the need for reflex testing (No Additional charge for genotyping). Your current HPV reflex rules that are setup per your standing reflex orders will be eliminated with this new test. Only 1 ml of patient sample is required, reducing the risk of QNS. We are now offering the **cobas**® HPV Test for all your HPV testing needs: ASC-US Reflex, Co-testing, and Primary Screening. The new HPV High Risk test will go live and be orderable on March 22, 2022, the test codes are HPVHR/11069/LAB5314 and will relayed through normal IT update channels.

If you have any questions, please contact the laboratory supervisor directly:

Kara J. Parsons, MLS, MB (ASCP)<sup>CM</sup>

[kara.parsons@sparrow.org](mailto:kara.parsons@sparrow.org)

517-371-9422

Walid T. Khalife, Ph.D., M.S.  
Director, Medical and Scientific Affairs  
Medical Director, Molecular Laboratory

James E. Richard, D.O.  
Medical Director, Laboratories